ライフサイエンスコーパス: bullous

1 f fever, widespread infiltrated plaques with bullous appearance, and variable involvement of the arms

2 Pemphigus vulgaris is a life threatening bullous autoimmune disease of the skin mediated by autoa

3 Bullous congenital ichthyosiform erythroderma (BCIE) is

4 antar epidermis, in comparison with cases of bullous congenital ichthyosiform erythroderma also due t

5 ted a mouse model for the human skin disease bullous congenital ichthyosiform erythroderma by gene ta

6 hthyosis is a distinct phenotypic variant of bullous congenital ichthyosiform erythroderma that has r

7 sults in a phenotype distinct from classical bullous congenital ichthyosiform erythroderma.

8 Mean subfoveal choroidal thickness in the bullous CSC group (463.1+/-83.1 mum) was not different c

9 ified in a greater proportion of eyes in the bullous CSC group (both P < 0.001).

10 The bullous CSC group demonstrated a greater number of pigme

11 More eyes in the bullous CSC group demonstrated hyperreflectivity around

12 Mean age of the bullous CSC group was 53.8 years.

13 In autoimmune bullous dermatoses (AIBD), autoantibodies induce blister

14 d aberrant cytokine expression in autoimmune bullous dermatoses (AIBDs), cytokine-targeting therapies

15 om the sera of some patients with linear IgA bullous dermatosis (LABD) recognize a 97 kDa antigen (LA

16 CBDC and its adult counter-part, linear IgA bullous dermatosis (LABD), are characterized by linear d

17 Bullous pemphigoid (BP) is a bullous dermatosis associated with autoantibodies direct

18 ent protein that is the target of linear IgA bullous dermatosis autoantibodies.

19 he autoimmune blistering disorder linear IgA bullous dermatosis specifically recognized bands of 120

20 f autoantibodies in patients with linear IgA bullous dermatosis.

21 Transient bullous dermolysis of the newborn (TBDN) is a blistering

22 area (0.561 vs. 0.499, p = 0.040), and less bullous disease (1.7 vs. 2.6, p = 0.011) compared with r

23 ship between percentage change in FEV(1) and bullous disease and inverse relationships between percen

24 r age of these patients with lung cancer and bullous disease as compared with those reported in the l

25 lysis bullosa acquisita (EBA), an autoimmune bullous disease caused by autoantibodies to type VII col

26 ctional epidermolysis bullosa is a heritable bullous disease caused by mutations found primarily in t

27 idermolysis bullosa acquisita, an autoimmune bullous disease characterized by autoantibodies against

28 (CT) of the chest in screening patients with bullous disease for lung cancer is discussed.

29 Pemphigus vulgaris (PV) is an autoimmune bullous disease in which autoantibodies against proteins

30 Chronic bullous disease of childhood (CBDC) is an autoimmune bli

31 We present six cases in which bullous disease of the lung and lung cancer coexisted, a

32 in the literature of an association between bullous disease of the lung and lung cancer; however, we

33 lysis bullosa acquisita (EBA) is an acquired bullous disease of the skin characterized by IgG autoant

34 Bullous pemphigoid (BP) is an autoimmune bullous disease of the skin characterized by subepiderma

35 was used to build a 45-item pilot Autoimmune Bullous Disease Quality of Life (ABQOL) questionnaire, d

36 Experts in bullous disease refined the pilot ABQOL before factor an

37 Disease Area Index (R = 0.42) and Autoimmune Bullous Disease Skin Disorder Intensity Score (R = 0.48)

38 the literature with lung cancer but without bullous disease suggests that the association between th

39 ic inflammation, peribronchial fibrosis, and bullous disease were assessed semiquantitatively.

40 idermolysis bullosa (DEB), a genetic mechano-bullous disease.

41 the latter being the most common autoimmune bullous disease.

42 t of IVIG in autoantibody-mediated cutaneous bullous diseases is to accelerate the degradation of pat

43 In conclusion, there are now three bullous diseases, bullous pemphigoid, herpes gestationis

44 t for >30 disorders, including numerous skin bullous diseases, myopathies, neuropathies, and even pro

45 ingle national referral center on autoimmune bullous diseases.

46 a referral university center for autoimmune bullous diseases.

47 olysis bullosa (DEB) is an inherited mechano-bullous disorder caused by mutations in the type VII col

48 ermolysis bullosa simplex (EBS) is a mechano-bullous disorder characterized by intraepidermal blister

49 olysis bullosa (DEB) is an inherited mechano-bullous disorder of skin caused by mutations in the type

50 n underlying vulvar dermatosis or autoimmune bullous disorder.

51 llosa (DEB) is a family of inherited mechano-bullous disorders caused by mutations in the human type

52 The pemphigus family of autoimmune bullous disorders is characterized by autoantibody bindi

53 idermolysis bullosa is a group of hereditary bullous disorders resulting from defects in several hemi

54 llosa (DEB) is a family of inherited mechano-bullous disorders that are caused by mutations in the ty

55 om a tertiary referral center for autoimmune bullous disorders.

56 ilation defects were shown in a patient with bullous emphysema, and ventilation-perfusion mismatches

57 disease characterized by severe subepidermal bullous eruptions and renal insufficiency with IgG autoa

58 rane (eg, the pemphigoid group of disorders [bullous, gestational, and mucous membrane]) or impaired

59 helial tears were seen in 95% of eyes in the bullous group and none of the eyes in the nonbullous CSC

60 Individuals with this variant present with bullous ichthyosis in early childhood and hyperkeratotic

61 In the blistering diseases bullous impetigo and staphylococcal scalded-skin syndrom

62 Bullous impetigo due to Staphylococcus aureus is one of

63 In bullous impetigo, Staphylococcus aureus spreads under th

64 or Fuchs endothelial dystrophy (260 eyes) or bullous keratopathy (15 eyes).

65 5 DMEK cases were performed for pseudophakic bullous keratopathy (2 cases, 1 in each cohort), and the

66 PK) for Fuchs endothelial dystrophy (FED) or bullous keratopathy (BK) in Asian eyes.

67 dothelial corneal dystrophy (FECD; n = 314), bullous keratopathy (BK; n = 31), and failed previous en

68 mpared with normal controls and pseudophakic bullous keratopathy (iatrogenic CE cell loss) specimens.

69 s endothelial corneal dystrophy (n = 28) and bullous keratopathy (n = 11).

70 SAEK graft failure (n = 3), and pseudophakic bullous keratopathy (n = 2).

71 gery (n = 127; 90%) followed by pseudophakic bullous keratopathy (n = 4; 4%) and regrafts (n = 9; 6.4

72 a), pseudophakic bullous keratopathy/aphakic bullous keratopathy (North America), and keratitis (Asia

73 mes than penetrating grafts for pseudophakic bullous keratopathy (P <0.001).

74 Fuchs endothelial dystrophy or pseudophakic bullous keratopathy (PBK) at a single institution.

75 FED and pseudophakic bullous keratopathy (PBK) corneal buttons were removed d

76 ched normal autopsy corneas and pseudophakic bullous keratopathy (PBK) corneas.

77 elial dystrophy and 9 eyes with pseudophakic bullous keratopathy (PBK) that underwent DSAEK, and 17 e

78 hs endothelial dystrophy (FED), pseudophakic bullous keratopathy (PBK), infection and other indicatio

79 hs endothelial dystrophy (FED), pseudophakic bullous keratopathy (PBK), or keratoconus who had underg

80 ly a Descemet membrane disorder), but not in bullous keratopathy (primarily an endothelial depletion)

81 was strongest in patients with pseudophakic bullous keratopathy (r = -0.62 [P = .01]).

82 captured by tear lipocalin from corneas with bullous keratopathy and dry eye.

83 erformed on eight cases each of pseudophakic bullous keratopathy and healthy corneas.

84 Fuchs endothelial dystrophy or pseudophakic bullous keratopathy at a single tertiary center.

85 primary surgical indication was pseudophakic bullous keratopathy at a single tertiary center.

86 he hypothesis that epithelial alterations in bullous keratopathy compromise the surface of the cornea

87 DNA damage was not detected in pseudophakic bullous keratopathy corneas, whereas it colocalized with

88 In contrast, none of the bullous keratopathy eyes showed any improvement througho

89 Fuchs endothelial dystrophy or pseudophakic bullous keratopathy from January 2006 through December 2

90 uchs' endothelial dystrophy and pseudophakic bullous keratopathy in patients without other vision-lim

91 MEK surgery in the treatment of pseudophakic bullous keratopathy in the presence of sf-IOL and if-IOL

92 Pseudophakic bullous keratopathy manifests an abnormal corneal ocular

93 ll and superficial cell layers were lower in bullous keratopathy specimens (1.6 vs. 2.0; P < 0.0001)

94 ers evident in sections was increased in the bullous keratopathy specimens compared with controls (0.

95 orated with antibodies to MUC16 was lower in bullous keratopathy specimens than in controls (0.5 vs.

96 Fuchs endothelial dystrophy and pseudophakic bullous keratopathy undergoing DSAEK surgery were includ

97 monstrated in a pre-clinical rabbit model of bullous keratopathy using a tissue-engineered endothelia

98 EK failure in pseudophakic bullous keratopathy was associated with center experienc

99 The reduction of layers expressing MUC1 in bullous keratopathy was not statistically significant.

100 rformed for Fuchs' dystrophy or pseudophakic bullous keratopathy was poorer than survival of penetrat

101 o be effective in symptomatic improvement of bullous keratopathy, and infectious keratitis but furthe

102 ycans from human corneas with chronic edema, bullous keratopathy, and keratoconus and from normal cor

103 the most common indication for PTK is still bullous keratopathy, as PTK can be successfully used whi

104 Fuchs endothelial dystrophy and pseudophakic bullous keratopathy, EK achieved better average best-cor

105 In our study of eyes with bullous keratopathy, endothelial keratoplasty under a pr

106 ssociated with Fuchs' endothelial dystrophy, bullous keratopathy, iridocorneal endothelial syndrome o

107 In eyes with pseudophakic bullous keratopathy, the EndoGlide group had a superior

108 s associated with them, such as pseudophakic bullous keratopathy, uveitis-glaucoma-hyphema syndrome,

109 of cellular adhesion molecules is altered in bullous keratopathy.

110 tes the dominant features of contemporaneous bullous keratopathy.

111 lay a significant role in the progression of bullous keratopathy.

112 ter graft survival in eyes with pseudophakic bullous keratopathy.

113 formed for Fuchs' dystrophy and pseudophakic bullous keratopathy.

114 secondary corneal edema due to pseudophakic bullous keratopathy.

115 p is strongest in patients with pseudophakic bullous keratopathy.

116 from Fuchs endothelial dystrophy and 5 with bullous keratopathy.

117 Fuchs endothelial dystrophy or pseudophakic bullous keratopathy.

118 st, Africa, and South America), pseudophakic bullous keratopathy/aphakic bullous keratopathy (North A

119 f anti-type VII collagen IgG increased after bullous lesions appeared.

120 re genetic condition typified by superficial bullous lesions following incident frictional trauma to

121 re genetic condition typified by superficial bullous lesions that result from frictional trauma to th

122 Histology showed bullous lesions with an epidermal-dermal separation.

123 levels observed before the inception of the bullous lesions.

124 salt-split indirect immunofluorescence, and bullous pemphigoid (BP) 230 and BP180-NC16A ELISAs.

125 Affiliated Hospitals with a new diagnosis of bullous pemphigoid (BP) between May 1, 1997 and Septembe

126 Bullous pemphigoid (BP) has been previously described to

127 Although predisposing factors for bullous pemphigoid (BP) have been recently established,

128 Bullous pemphigoid (BP) is a bullous dermatosis associat

129 Bullous pemphigoid (BP) is a subepidermal blistering dis

130 Bullous pemphigoid (BP) is a subepidermal blistering dis

131 Bullous pemphigoid (BP) is a subepidermal blistering dis

132 Bullous pemphigoid (BP) is an autoimmune bullous disease

133 Bullous pemphigoid (BP) is an autoimmune disease associa

134 Bullous pemphigoid (BP) is an autoimmune disease charact

135 Bullous pemphigoid (BP) is an autoimmune skin disease ch

136 Bullous pemphigoid (BP) is an autoimmune skin disease ch

137 Bullous pemphigoid (BP) is an autoimmune skin disease ch

138 Bullous pemphigoid (BP) is an autoimmune skin-blistering

139 Bullous pemphigoid (BP) is an autoimmune subepidermal bl

140 Bullous pemphigoid (BP) is an autoimmune subepidermal bl

141 Bullous pemphigoid (BP) is an autoimmune subepidermal bl

142 Bullous pemphigoid (BP) is an inflammatory subepidermal

143 Bullous pemphigoid (BP) is an inflammatory subepidermal

144 Bullous pemphigoid (BP) is by far the most frequent auto

145 Bullous pemphigoid (BP) is characterized by the depositi

146 tibodies from the sera of some patients with bullous pemphigoid (BP) react with a 180 kDa protein ter

147 Bullous pemphigoid (BP), a common autoimmune blistering

148 ation has long been a histologic hallmark of bullous pemphigoid (BP), a subepidermal autoimmune blist

149 ermal separation in an experimental model of bullous pemphigoid (BP), an autoimmune disease.

150 targeted by autoantibodies in patients with bullous pemphigoid (BP), and absent in patients with one

151 sera from patients with pemphigus vulgaris, bullous pemphigoid (BP), and chronic atopic and chronic

152 tients with a blistering skin disease called bullous pemphigoid (BP), is a transmembrane component of

153 rom patients with MMP, 1 of 50 patients with bullous pemphigoid (BP), none of 7 with pemphigus, and 3

154 e used IgG passive transfer murine models of bullous pemphigoid (BP), pemphigus foliaceus (PF), and p

155 The outcome of bullous pemphigoid (BP), the most frequent autoimmune sk

156 eurological disorders may be associated with bullous pemphigoid (BP).

157 reported sequence of the 180 kDa antigen in bullous pemphigoid (BPAg2).

158 systemic lupus erythematosus (BSLE) (n = 3), bullous pemphigoid (n = 16), pemphigus (n = 11), and nor

159 Pemphigus vulgaris (n=40, USA and Japan), bullous pemphigoid (n=40, USA), and healthy donors (n=55

160 p randomised controlled trial of adults with bullous pemphigoid (three or more blisters at two or mor

161 ibodies directed against the NC16A domain of bullous pemphigoid 180 (collagen XVII), a transmembrane

162 s that bind to this immunodominant region of bullous pemphigoid 180 are capable of inducing a skin di

163 d patients, all of whom had circulating anti-bullous pemphigoid 180 autoantibodies, showed a specific

164 ned autoantibody-reactive site recognized by bullous pemphigoid and herpes gestationis sera) and the

165 th two other autoimmune blistering diseases, bullous pemphigoid and herpes gestationis.

166 ednisolone for short-term blister control in bullous pemphigoid and significantly safer in the long-t

167 These mice represent a bullous pemphigoid animal model featuring pruritus in im

168 esmosomal transmembrane protein, the 180 kDa bullous pemphigoid antigen (BP180), also known as type X

169 n utilizing primers specific for the 230 kDa bullous pemphigoid antigen (BPAG1), the 180 kDa bullous

170 The 180-kDa bullous pemphigoid antigen (BPAG2) is a candidate gene/p

171 lous pemphigoid antigen (BPAG1), the 180 kDa bullous pemphigoid antigen (BPAG2), the alpha6 and beta4

172 mma, activated the skin-specific promoter of bullous pemphigoid antigen 1 (BPAG-1).

173 Bullous pemphigoid antigen 1 (BPAG1) is a member of the

174 Bullous pemphigoid antigen 1 (BPAG1) is a member of the

175 They contain mutations in the gene encoding Bullous Pemphigoid Antigen 1 (BPAG1), or dystonin.

176 Bullous pemphigoid antigen 1 (BPAG1-e, also known as BP2

177 and is identical to the neuronal isoform of bullous pemphigoid antigen 1 (BPAG1-n).

178 Other plakins, such as bullous pemphigoid antigen 1 and microtubule and actin c

179 Disruption of the BPAG1 (bullous pemphigoid antigen 1) gene results in progressiv

180 proteins, to which envoplakin, desmoplakin, bullous pemphigoid antigen 1, and plectin belong.

181 led-coil domain of the epithelial isoform of bullous pemphigoid antigen 1, BPAG1-e (also known as BP2

182 gnized desmoplakin and plectin, and, weakly, bullous pemphigoid antigen 1.

183 Autoreactive T cells to an epitope of bullous pemphigoid antigen 180 kilodaltons were identifi

184 he beta4 integrin-associated plakin protein, bullous pemphigoid antigen 1e (BPAG1e) functions as a sc

185 integrin or knockdown of the plakin protein Bullous Pemphigoid Antigen 1e (BPAG1e).

186 Bullous pemphigoid antigen 2 (BPAG2) is targeted by auto

187 Skin grafts from mice expressing human bullous pemphigoid antigen 2 (hBPAG2) in epidermal basem

188 5 (p < 0.05), and in skin from patients with bullous pemphigoid antigen 2 mutations (n = 3) the count

189 roteins such as the integrin alpha6beta4 and bullous pemphigoid antigen 2 within the hemidesmosomes a

190 D97 is a component of the shed ectodomain of bullous pemphigoid antigen 2.

191 s reduced dynamics, and fails to recruit its bullous pemphigoid antigen binding partners.

192 The bullous pemphigoid antigen BPAG1 is required for keratin

193 ression of zinc finger protein 185 (ZNF185), bullous pemphigoid antigen gene (BPAG1), and prostate se

194 and attest to the importance of the 180-kDa bullous pemphigoid antigen in the attachment of the epid

195 A second bullous pemphigoid antigen of 180 kDa (BP180/BPAG2) is a

196 roteins and include desmoplakin, the 230 kDa bullous pemphigoid antigen, and envoplakin.

197 protein interacting with Nck (SPIN90/WISH), bullous pemphigoid antigen-1, and calcium channel beta2.

198 s of BMZ proteins: one enriched with the two bullous pemphigoid antigens (BP230, BP180) and one enric

199 he alpha6beta4 integrin, plectin, and BPAGs (bullous pemphigoid antigens).

200 Pemphigus and bullous pemphigoid are autoantibody-mediated blistering

201 Pemphigus and bullous pemphigoid are distinct autoimmune blistering di

202 has recently demonstrated that reactivity of bullous pemphigoid autoantibodies to the BP180 ectodomai

203 tandard techniques for detecting circulating bullous pemphigoid autoantibodies, including other enzym

204 h the 180 and 230 kDa proteins recognized by bullous pemphigoid autoantibodies, LABD97 has been thoug

205 t of the hemidesmosome plaque is the 230-kDa bullous pemphigoid autoantigen (BP230/BPAG1), which conn

206 ns regarding an experimental murine model of bullous pemphigoid by showing that the plasminogen/plasm

207 th BP underwent clinical evaluation with the Bullous Pemphigoid Disease Activity Index (BPDAI); and 3

208 tream from the MCW-1 domain, the predominant bullous pemphigoid epitope.

209 In the literature, patients with bullous pemphigoid have been reported to have itch witho

210 Bullous pemphigoid is a blistering skin disease characte

211 Bullous pemphigoid is a blistering skin disorder with in

212 ostic assays and expertise and classified as bullous pemphigoid or epidermolysis bullosa acquisita.

213 stemic lupus erythematosus patients (n = 3), bullous pemphigoid patients (n = 15), and normal humans

214 T cells from eight of 12 bullous pemphigoid patients, all of whom had circulating

215 e examined the autoimmune T cell response in bullous pemphigoid patients.

216 sease-specific autoantibodies in the sera of bullous pemphigoid patients.

217 reas the predominant epitope identified with bullous pemphigoid sera is located in the noncollagenous

218 Of 50 randomly selected bullous pemphigoid sera tested, 47 (94%) were positive i

219 Interestingly, all three of the bullous pemphigoid sera that were negative in this assay

220 nic target of autoantibodies associated with bullous pemphigoid, a blistering skin disease.

221 mice would also be resistant to experimental bullous pemphigoid, a disease with a pathogenesis though

222 , pemphigus foliaceous, pemphigus, vulgaris, bullous pemphigoid, and benign chronic pemphigus, howeve

223 heir first year of life, with uncontrollable bullous pemphigoid, colitis, and proteinuria.

224 d diagnosis of pemphigus vulgaris/foliaceus, bullous pemphigoid, epidermolysis bullosa acquisita, muc

225 usion, there are now three bullous diseases, bullous pemphigoid, herpes gestationis, and cicatricial

226 l patients with immunopathologic findings of bullous pemphigoid, itch, and no blisters.

227 Sera from patients with bullous pemphigoid, pemphigus vulgaris, and cicatricial

228 inducing a skin disease that closely mimics bullous pemphigoid, supporting the hypothesis that epito

229 icture may be indistinguishable from that of bullous pemphigoid, the latter being the most common aut

230 mmon in elderly patients, including scabies, bullous pemphigoid, transient acantholytic dermatosis, a

231 Earlier preliminary studies in humans with bullous pemphigoid, which is also associated with excess

232 The most common of these diseases is bullous pemphigoid, which mainly affects older people an

233 n that contains all four of the well-defined bullous pemphigoid-associated antigenic sites.

234 In the inflammatory (bullous pemphigoid-like) EBA variant, autoantibody bindi

235 as valuable medications in the treatment of bullous pemphigoid.

236 en of the autoimmune skin blistering disease bullous pemphigoid.

237 s in a mouse model of the autoimmune disease bullous pemphigoid.

238 in NC16A are involved in the pathogenesis of bullous pemphigoid.

239 he development of the autoimmune response in bullous pemphigoid.

240 ermal blistering disease that closely mimics bullous pemphigoid.

241 associated with the blistering skin disease, bullous pemphigoid.

242 e relevant in the diagnosis and treatment of bullous pemphigoid.

243 pemphigoid and help distinguishing them from bullous pemphigoid.

244 nd for the clinical benefit of patients with bullous pemphigoid.

245 dase-IV inhibitor-associated noninflammatory bullous pemphigoid.

246 ut blisters had immunopathologic findings of bullous pemphigoid.

247 hout skin lesions can be the only symptom of bullous pemphigoid.

248 vulgaris were diagnosed; there was 1 case of bullous pemphigoid; and 1 suspected case of paraneoplast

249 form of the disease, characterized by large bullous peripheral schisis involving the posterior pole,

250 eveloped moderate to severe tractional RD or bullous RD in the control group by day 10 compared with

251 eral nonperfusion occurred only in eyes with bullous retinal detachment (38% of cases).

252 Bullous retinal detachment is a rare manifestation of ch

253 s who sought treatment from the authors with bullous retinal detachment resulting from CSC between Ja

254 Consecutive cases of chronic CSC without bullous retinal detachment, seen during the same period,

255 ndus examination was characterized by severe bullous retinal schisis with pre-retinal and intraretina

256 e psoriasis (5648), mild psoriasis (85 232), bullous skin diseases (4284), ulcerative colitis (12 203

257 phigus Disease Area Index (PDAI), Autoimmune Bullous Skin Disorder Intensity Score (ABSIS), and Pemph

258 and the recently described ABSIS (autoimmune bullous skin disorder intensity score) instrument.

259 ested serum from patients with EBA (n = 24), bullous systemic lupus erythematosus (BSLE) (n = 3), bul

260 bodies are often detectable in patients with bullous systemic lupus erythematosus (BSLE).

261 , we tested sera from EBA patients (n = 32), bullous systemic lupus erythematosus patients (n = 3), b

262 Twenty-six of 32 EBA sera and two of three bullous systemic lupus erythematosus sera reacted with t